| Literature DB >> 2572198 |
T Hattori1, S Ikematsu, A Koito, S Matsushita, Y Maeda, M Hada, M Fujimaki, K Takatsuki.
Abstract
Glycyrrhizin (GL) at a dose of 400-1600 mg/day (7.2-30.8 mg/kg/day) was administered intravenously for a period of more than a month, on 6 separate occasions, to 3 hemophiliacs with acquired immune deficiency syndrome (AIDS). Human immunodeficiency virus type 1 (HIV-1) p24 antigen was detected at the beginning of 5 of the 6 treatment courses. Viral antigen was not detected at the end of or during 3 of the 5 treatment courses and decreased to a low level following the 2 other courses. These findings suggest that GL might inhibit HIV-1 replication in vivo.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2572198 DOI： 10.1016/0166-3542(89)90035-1
Source DB: PubMed Journal: Antiviral Res ISSN： 0166-3542 Impact factor: 5.970